In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis

European Respiratory Journal

Volumn 44, Issue 3, 2014, Pages 808-811

  Bolhuis, Mathieu S ^a   Van Der Laan, Tridia ^b   Kosterink, Jos G W ^a,c   Van Der Werf, Tjip S ^a   Van Soolingen, Dick ^b,d   Alffenaar, Jan Willem C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; ETHAMBUTOL; ISONIAZID; LINEZOLID; RIFAMPICIN; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONCENTRATION RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; IN VITRO STUDY; LETTER; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; HEALTH CARE FACILITY; HUMAN; MICROBIAL SENSITIVITY TEST; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ACETAMIDES; ANTI-BACTERIAL AGENTS; BIOLOGICAL SPECIMEN BANKS; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OXAZOLIDINONES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84907303247     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00041314     Document Type: Letter

References (15)

1. Falzon D, Jaramillo E, Schunemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
2. De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J 2013; 41: 1386-1392.
3. Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009; 34: 387-393.
4. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
5. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367: 1508-1518.
6. Truffot-Pernot C, Lounis N, Grosset JH, et al. Clarithromycin is inactive against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995; 39: 2827-2828.
7. Honeybourne D, Kees F, Andrews JM, et al. The levels of clarithromycin and its 14-hydroxy metabolite in the lung. Eur Respir J 1994; 7: 1275-1280.
8. Cavalieri SJ, Biehle JR, Sanders WE Jr. Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995; 39: 1542-1545.
9. van Klingeren B, Dessens-Kroon M, van der Laan T, et al. Drug susceptibility testing of Mycobacterium tuberculosis complex by use of a high-throughput, reproducible, absolute concentration method. J Clin Microbiol 2007; 45: 2662-2668.
10. Alffenaar JW, van der Laan T, Simons S, et al. Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480. Antimicrob Agents Chemother 2011; 55: 1287-1289.
11. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
12. Bolhuis MS, Altena RV, Soolingen DV, et al. Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. Eur Respir J 2013; 42: 1614-1621.
13. Srivastava S, Peloquin CA, Sotgiu G, et al. Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Eur Respir J 2013; 42: 1449-1453.
14. Diel R, Loddenkemper R, Zellweger JP, et al. Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. Eur Respir J 2013; 42: 785-801.
15. D'Ambrosio L, Dara M, Tadolini M, et al. Tuberculosis elimination: theory and practice in Europe, Eur Respir J 2014; 43: 1410-1420.